Skip Navigation LinksHome > December 2002 - Volume 25 - Issue 6 > Excellent Long-Term Survival in Patients With Early-Stage Pr...
American Journal of Clinical Oncology:
Article

Excellent Long-Term Survival in Patients With Early-Stage Primary Bone Lymphoma Treated With Doxorubicin-Based Chemotherapy and Local Radiotherapy.

Stein, Moshe Efraim M.D.; Epelbaum, Ron M.D.; Zaidan, Jamal M.D.; Kuten, Avraham M.D.; Ben-Schachar, Menachem M.D.; Haim, Nissim M.D.

Collapse Box

Abstract

Primary bone lymphoma accounts for less than 5% of primary extranodal presentations, and the majority are of the diffuse, large cell, B-cell type. The study presents the authors' 21 years of experience (1979-2000) in ten patients with early stage (IE-IIE) primary bone lymphoma. All patients were treated with doxorubicin-based chemotherapy. Seven received consolidation radiotherapy to an area encompassing the primary tumor with generous margins, including the adjacent soft tissues, and in two stage IIE patients also to the regional lymph nodes. Mean total dose was 3989 cGy. Nine patients are alive with no evidence of recurrent disease. There are no severe late side effects, and only one patient died due to therapy-resistant small cell lung cancer (second primary), while in complete remission from his primary lymphoma. Albeit retrospective in nature with a small patient accrual, this study demonstrates that primary bone lymphoma is a curable disease following aggressive doxorubicin-based chemotherapy. The exact rule of radiation therapy is yet to be determined.

© 2002 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us

Twitter
twitter.com/AJCOonline

For additional oncology content, visit LWW Oncology Journals on Facebook.